Sugi Predict

Sugi Predict / Compounds / SCHEMBL14645283

SCHEMBL14645283

SCHEMBL14645283

COC(=O)Cc1cc(-c2ccc(Br)s2)sc1-c1ccc(-c2sc(-c3ccc(Br)s3)cc2CC(=O)OC)s1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.34
▸ LMNA P02545 2/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ TP53 P04637 3/20 0.33
▸ RXFP1 Q9HBX9 3/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ CES2 O00748 1/20 0.33
▸ CES1 P23141 1/20 0.33
▸ ACACA Q13085 1/20 0.33
▸ HSP90AB1 P08238 1/20 0.33
▸ MAPT P10636 2/20 0.33
▸ ALDH1A1 P00352 4/20 0.33
▸ GAA P10253 2/20 0.33
▸ GLA P06280 2/20 0.33
▸ EGFR P00533 1/20 0.33
▸ HPGD P15428 3/20 0.32
▸ GFER P55789 1/20 0.32
▸ SNCA P37840 1/20 0.32
▸ CYP4F2 P78329 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15695231 0.96 RXFP1 (0.33) KDM4ELMNAABL1POLBTP53
SCHEMBL14645328 0.86 HSP90AB1 (0.37) KDM4ELMNATP53KMT2AACACA
SCHEMBL14645525 0.84 NPSR1 (0.37) KDM4ELMNATP53MAPTALDH1A1
SCHEMBL14773874 0.84 ALDH1A1 (0.38) KDM4ELMNAKMT2AACACAHSP90AB1
SCHEMBL9976578 0.84 ACACA (0.33) KDM4EACACAHSP90AB1ALDH1A1GAA
SCHEMBL15695230 0.83 TP53 (0.33) KDM4ETP53RXFP1KMT2AACACA
SCHEMBL14645594 0.83 MEN1 (0.37) KDM4ELMNAABL1POLBTP53
SCHEMBL9976534 0.83 HPGD (0.40) KDM4EPOLBKMT2AACACAALDH1A1
SCHEMBL15695223 0.82 MAPT (0.35) KDM4ELMNATP53KMT2AACACA
SCHEMBL14645436 0.81 KDM4E (0.33) KDM4ETP53ACACAHSP90AB1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2817304-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BioChromix NewCo AB (SE) 2014-12-31 — — EP claimed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 — — WO claimed
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 — — US disclosed
US-9359311-B2 Substituted aromatic oligomers NEUROSCIOS GMBH (AT) 2016-06-07 — — US disclosed
EP-2817304-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BioChromix NewCo AB (SE) 2014-12-31 — — EP disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 — — US disclosed
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB 2014-05-15 — — US disclosed
WO-2013036196-A1 NOVEL THIOPHENE COMPOUNDS AND METHOD FOR IN VIVO IMAGING BIOCHROMIX AB (SE) 2013-03-14 — — WO disclosed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 — — WO disclosed
WO-2013009259-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY BIOCHROMIX PHARMA AB (SE) 2013-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135322-A1 NOVEL COMPOUNDS AND THEIR USE IN THERAPY PRNP, TBCA, HSPA5 KDM4E 4549/4885LMNA 262/4885ABL1 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.